ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER (ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER).
Ceftriaxone is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
| Metabolism | Ceftriaxone is not metabolized; it is excreted unchanged primarily in urine (50-60%) and bile (40-50%). |
| Excretion | Renal (33-67% unchanged) and biliary (40-50% unchanged and microbiologically inactive metabolite). Approximately 50% excreted in urine, 50% in feces. |
| Half-life | Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged up to 15 hours in elderly; significantly increased in renal impairment (up to 20-30 hours in ESRD). |
| Protein binding | Protein binding: ~85-95%, primarily to albumin. Binding is saturable and decreases with higher concentrations. |
| Volume of Distribution | Volume of distribution: 0.12-0.14 L/kg (7-10 L in adults), indicating primarily extracellular distribution. Higher Vd in neonates (0.3-0.5 L/kg). |
| Bioavailability | Bioavailability: IM administration: 100% (due to complete absorption). |
| Onset of Action | IV: Rapid, within 15-30 minutes. IM: 1-2 hours. |
| Duration of Action | Duration: Approximately 24 hours due to long half-life, allowing once-daily dosing for most infections. Clinical effect persists for 24 hours. |
1-2 g IV or IM once daily; maximum 4 g/day. For serious infections, 2 g IV every 12 hours.
| Dosage form | INJECTABLE |
| Renal impairment | No adjustment required for GFR >5 mL/min. For GFR <5 mL/min (including dialysis), maximum dose 2 g/day. |
| Liver impairment | No adjustment recommended for Child-Pugh Class A or B. For Child-Pugh Class C, use with caution; no specific dosage guidelines. |
| Pediatric use | 50-75 mg/kg/day IV/IM once daily; maximum 2 g/day. For meningitis, 100 mg/kg/day once daily (max 4 g/day). |
| Geriatric use | No specific adjustment; use lowest effective dose based on renal function. Monitoring of renal function recommended. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER (ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER).
| Breastfeeding | Ceftriaxone is excreted into human milk in low concentrations (M/P ratio not established; estimated less than 4% of maternal dose). It is considered compatible with breastfeeding by the American Academy of Pediatrics. However, monitor infant for potential gastrointestinal disturbances (diarrhea, candidiasis) and allergic reactions. |
| Teratogenic Risk | Ceftriaxone (Rocephin) is FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. In humans, no adequate controlled studies in pregnant women exist. However, ceftriaxone crosses the placenta. First trimester: Theoretical risk of kernicterus in neonates due to bilirubin displacement, but not confirmed. Second and third trimesters: Use only if clearly needed; risk of biliary sludging in mother and neonate, but no known teratogenicity. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to ceftriaxone or any cephalosporin","Hyperbilirubinemic neonates, especially premature infants (risk of bilirubin encephalopathy)","Do not administer with calcium-containing IV solutions in neonates (risk of precipitation)"]
| Precautions | ["Hypersensitivity reactions including anaphylaxis","Clostridioides difficile-associated diarrhea","Hemolytic anemia","Biliary pseudolithiasis and pancreatitis","Superinfection","Neuromuscular blockade in myasthenia gravis","Seizures with high doses or renal impairment"] |
Loading safety data…
| Fetal Monitoring | Maternal: Renal function, hepatic function, and CBC with differential during prolonged therapy; signs of superinfection or allergic reactions. Fetal/Neonatal: No specific monitoring required, but if used near term, observe neonate for signs of kernicterus (jaundice, lethargy) or biliary sludging (abdominal distension, vomiting). |
| Fertility Effects | No known adverse effects on human fertility. Animal studies have not shown impaired fertility at clinically relevant doses. |